Prognosis of patients with unstable angina or acute myocardial infarction treated with calcium channel antagonists

American Journal of Cardiology

Volumn 77, Issue 16, 1996, Pages 22D-25D

  Ferrari, Roberto ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTHIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; NIFEDIPINE; PHENYLALKYLAMINE; VERAPAMIL;

ACUTE HEART INFARCTION; ARTICLE; CORONARY ARTERY DISEASE; DRUG CHOICE; DRUG CLASSIFICATION; DRUG PREFERENCE; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; PROGNOSIS; UNSTABLE ANGINA PECTORIS;

EID: 0030001448     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00304-9     Document Type: Article

References (44)

1. Horton R. Spinning the risks and benefits of calcium antagonists. Lancet 1995;346:586.
2. Messerli FH. Are calcium antagonists safe? Lancet 1995;346:767-768.
3. Poole-Wilson P. Letter to the Editor. Lancet 1995;346:769-770.
4. Psaty BM, Heckbert SR, Koepsell TD, Siskovich DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-625.
5. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction. JAMA 1995;274:654-655.
6. Messerli FH. Cardioprotection. Not all calcium antagonists are graded equal. Am J Cordiol 1990;60:855-856.
7. Ferrari R, Cucchini F, Bolognesi R, Bachetti T, Boraso A, Bernocchi P, Gaia G, Visioli O. How do calcium antagonists differ in clinical practice? Cardiovasc Drugs Ther 1994;8:565-575.
8. Pahor M, Guralnick JM, Corti M-C, Foley DJ, Carbonin P, Havlik RJ. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995;43:5-7.
9. Rehnqvist N, Hjemdahl P, Billing E, Bjorkander I, Eriksson SV, Forslund L, Held C, Nasman P, Hakan-Wollen N. Prevention of cardiac events in patients with angina pectoris: results of the APSIS Study. Eur Heart J 1995;16(suppl H):18.
10. Branagan JP, Walsh K, Kelly P, Collins WC, McCafferty D, Walsh MJ. Effect of early treatment with nifedipine in suspected acute myocardial infarction. Eur Heart J 1986;7:859-865.
11. Eisenberg PR, Lee RG, Biello DR, Geltmann EM, Jaffe AS. Chest pain after non transmural infarction: the absence of remediable coronary spasm. Am Heart J 1985;110:515-521.
12. Erbel R, Pop T, Meinertz T, Olshausen KV, Treese N, Henrichs KJ, Schuter CJ, Rupprecht HJ, Schlurmann W, Meyer J. Combination of calcium channel blocker and thrombolytic therapy in acute myocardial infarction. Am Heart J 1988;115:529-538.
13. Gordon GD, Mabin TA, Issacs S, Lloyd EA, Eichler HG, Opie LH. Hemodynamic effects of sublingual nifedipine in acute myocardial infarction. Am J Cardiol 1984;53:1228-1232.
14. Gottlieb SO, Becker L, Weiss JI, Shapiro EP, Chandra NC, Flaherty JT, Gottlieb SH, Ouyang P, Mellits ED, Townsend SN, Weisfeldt ML, Healy B, Gerstenblith G. Nifedipine in acute myocardial infarction: an assessment of left ventricular function, infarct size, and infarct expansion: a double-blind randomized placebo controlled trial. Br Heart J 1988;59:411-418.
15. Jaffe AS, Biello DR, Sobel BE, Geltmann EM. Enhancement of metabolism of jeopardized myocardium by nifedipine. Int J Cardiol 1987;15:77-89.
16. Loogna E, Sylven C, Groth T, Mogensen L. Complexity of enzyme release during acute myocardial infarction in a controlled study with early nifedipine treatment. Eur Heart J 1985;6:114-119.
17. Muller JE, Morrison J, Stone PH, Rude RE, Rosner B, Roberts R, Pearle DL, Turi ZG, Schneider JF, Serfas DH, Tate C, Scheiner E, Sobel BE, Hennekens CH, Braunwald E. Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. Circulation 1984;69:740-747.
18. Sirnes PA, Overskeid K, Pedersen TR, Bathen J, Drivenes A, Frøland GS, Kjekshus JK, Landmark K, Rokset R, Sirnes KE, Sundoy A, Torjussen BR, Westlund KM, Wik BA. Evaluation of infarct size during the early use of nifedipine in patients with acute myocardial infarction: the Norwegian nifedipine multicentre trial. Circulation 1984;70:638-644.
19. SPRINT Study Group. The secondary prevention re-infarction Israeli nifedipine trial (SPRINT) II: design and methods, results. Eur Heart J 1988;9(suppl 1):350A.
20. Walker L, Mackenzie A, Adgey J. Effect of nifedipine on enzymatically estimated infarct size in the early phase of acute myocardial infarction. Br Heart J 1988;39:403-410.
21. Wilcox RG, Hampton JR, Banks DC, Birkhead JS, Brooksby JS. Trial of early nifedipine in acute myocardial infarction: the Trent Study. Br Med J 1986;293:1204-1208.
22. Gibson RS, Boden WE, Theroux P, Strauss HD, Pratt CM. Diltiazem and re-infarction in patients with non-Q wave myocardial infarction. N Engl J Med 1986;315:423-429.
23. Moss A, Oakes D, Benhorin J. Effect of diltiazem on outcome in postinfarction patients with and without left ventricular dysfunction. Circulation 1988;78(suppl II):97A.
24. Danish Study Group on Verapamil in myocardial infarction. Verapamil in acute myocardial infarction. Eur Heart J 1984;5:516-528.
25. Bussmann WD, Ser W, Gruengrass M. Reduction of creatine kinase and creatine kinase-MB indexes of infarct size by intravenous verapamil. Am J Cardiol 1984;54:1224-1230.
26. Crea F, Deanfield J, Crean P, Sharom M, Davies G, Maseri A. Effects of verapamil in preventing early post-infarction angina and reinfarction. Am J Cardiol 1985;55:900-904.
27. Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction. Am J Cardiol 1990;66:779-785.
28. Ferrari R, Albertini A, Curello S, Ceconi C, Di Lisa F, Raddino R, Visioli O. Myocardial recovery during post-ischemic reperfusion: effects of nifedipine, calcium and magnesium. J Mol Cell Cardiol 1986;18:487-488.
29. Ferrari R, Boffa GM, Ceconi C, Curello S, Boraso A, Ghielmi S, Cargnoni A. Effect of D-600 on ischemic and reperfused rabbit myocardium: relation with timing modality of administration. Basic Res Cardiol 1989;84:606-622.
30. Ferrari R, Raddino R, Ceconi C, Curello S, Ghielmi S, Visioli O. Prolonged protective effect of the calcium antagonist anipamil on the ischemic reperfused rabbit myocardium: comparison with verapamil. Cardiovasc Drugs Ther 1989;3:403-412.
31. Henry PD, Shuchleib R, Clark RE, Perez JE. Effect of nifedipine on myocardial ischemia: analysis of collateral flow, pulsatile heat and regional muscle shortening. Am J Cardiol 1979;44:817-824.
32. Nayler WG, Ferrari R, Williams A. Protective effect of pretreatment with verapamil, nifedipine and propranolol on mitochondrial function in the ischemic and reperfused myocardium. Am J Cardiol 1980;46:242-248.
33. Nayler WG. Protection of the myocardium against post-ischemic reperfusion damage. J Thorac Cardiovasc Surg 1982;84:897-905.
34. Perez JE, Sobel BE, Henry PD. Improved performance of ischemic canine myocardium in response to nifedipine and diltiazem. Am J Physiol 1980;239:H658-H663.
35. Reimer KA, Lowe E, Jennings RB. Effect of the calcium antagonist verapamil on necrosis following temporary coronary artery occlusion in dogs. Circulation 1977;55:581-587.
36. Weishaar RE, Bing BJ. The beneficial effects of a calcium channel blocker, diltiazem, on the ischemic-reperfused heart. J Mol Cell Cardiol 1980;12:993-1009.
37. Yoon Sb, McMillin-Wood JB, Michael LH, Lewis RM, Entman ML. Protection of canine cardiac mitochondrial function by verapamil cardioplegia during ischemic arrest. Circ Res 1985;56:704-708.
38. Held P, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. Br Med J 1989;299:1187-1192.
39. Yusuf S, Held P, Furberg CD. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991;67:1295-1297.
40. Ferrari R, Visioli O. Protective effects of calcium antagonists against ischemia and reperfusion damage. Drugs 1991;42(suppl 1):14-27.
41. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-1331.
42. Opie LH, Messerli FH. Nifedipine and mortality. Grave defects in the dossier. Circulation 1995;92:1068-1073.
43. Kloner RA. Editorial: nifedipine in ischemic heart disease. Circulation 1995;92:1074-1078.
44. Yusuf S. Calcium antagonists in coronary artery disease and hypertension. Time for reevalaution? Circulation 1995;92:1079-1082.